Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932523 | 0.79 | — | — | |
| SCHEMBL1468704 | 0.78 | FFAR3 (0.62) | FFAR3ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL20002734 | 0.78 | FFAR3 (0.36) | FFAR3ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL20255525 | 0.78 | FFAR3 (0.62) | FFAR3ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL10203449 | 0.78 | FFAR3 (0.62) | FFAR3ALDH1A1CYP2C9CYP2C19LMNA | |
| SCHEMBL9876428 | 0.76 | — | — | |
| SCHEMBL19706806 | 0.76 | TDP1 (0.35) | FFAR3ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5277555 | 0.76 | FFAR3 (0.31) | FFAR3 | |
| SCHEMBL11290997 | 0.75 | — | — | |
| SCHEMBL2275288 | 0.74 | CYP1A2 (0.46) | FFAR3ALDH1A1LMNACYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020127200-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20060293326-A1 | 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases | BAYER HEALTHCARE AG (DE) | 2006-12-28 | — | — | US | disclosed |
| US-7087605-B2 | 5-Ethyl-imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| EP-1399439-B1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1397363-B1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | EPX, TPMT, IL5 | FFAR3 2054/4885ALDH1A1 1621/4885CYP2C9 1066/4885 |
| US-20060293326-A1 | 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases | REL, AHR, SULT2A1 | FFAR3 1193/4885ALDH1A1 574/4885CYP2C9 200/4885 |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | CYP3A5, CYP11B2, CNR2 | FFAR3 412/4885ALDH1A1 335/4885CYP2C9 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.